| 2 | Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. (Singla S, Putman M, Liew J, Gordon K) Lancet Rheumatol 2023 Apr;5(4):e200-e207 102 Citations |
| 1 | Anti-IL 23 biologics for the treatment of plaque psoriasis. (Vu A, Ulschmid C, Gordon KB) Expert Opin Biol Ther 2022 Dec;22(12):1489-1502 22 Citations |
| 1 | Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. (Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG) J Allergy Clin Immunol 2022 Jun;149(6):2010-2020.e8 69 Citations |
| 1 | Targeting the CCR6/CCL20 Axis in Entheseal and Cutaneous Inflammation. (Shi Z, Garcia-Melchor E, Wu X, Getschman AE, Nguyen M, Rowland DJ, Wilson M, Sunzini F, Akbar M, Huynh M, Law T, Raychaudhuri SK, Raychaudhuri SP, Volkman BF, Millar NL, Hwang ST) Arthritis Rheumatol 2021 Dec;73(12):2271-2281 23 Citations |
| 1 | Interleukin-23 receptor signaling by interleukin-39 potentiates T cell pathogenicity in acute graft-versus-host disease. (Bastian D, Sui X, Nguyen HD, Wu Y, Schutt S, Tian L, Sofi MH, Liu Y, Martin P, Bartee E, Yu XZ) Am J Transplant 2021 Nov;21(11):3538-3549 16 Citations |
| 1 | Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. (Reich K, Song M, Li S, Jiang J, Youn SW, Tsai TF, Choe YB, Huang YH, Gordon KB) J Dermatol 2019 Dec;46(12):1141-1152 15 Citations |
| 1 | Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. (Elewski B, Menter A, Crowley J, Tyring S, Zhao Y, Lowry S, Rozzo S, Mendelsohn AM, Parno J, Gordon K) J Dermatolog Treat 2020 Dec;31(8):763-768 14 Citations |
| 1 | Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. (Gordon KB, Armstrong AW, Foley P, Song M, Shen YK, Li S, Muñoz-Elías EJ, Branigan P, Liu X, Reich K) J Invest Dermatol 2019 Dec;139(12):2437-2446.e1 97 Citations |
| 1 | IL-23 inhibitors for moderate-to-severe psoriasis. (Ibler E, Gordon KB) Semin Cutan Med Surg 2018 Sep;37(3):158-162 13 Citations |
| 2 | Protein engineering of the chemokine CCL20 prevents psoriasiform dermatitis in an IL-23-dependent murine model. (Getschman AE, Imai Y, Larsen O, Peterson FC, Wu X, Rosenkilde MM, Hwang ST, Volkman BF) Proc Natl Acad Sci U S A 2017 Nov 21;114(47):12460-12465 53 Citations |
| 1 | Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. (Li N, Xu W, Yuan Y, Ayithan N, Imai Y, Wu X, Miller H, Olson M, Feng Y, Huang YH, Jo Turk M, Hwang ST, Malarkannan S, Wang L) Sci Rep 2017 May 03;7(1):1485 94 Citations |
| 1 | Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients. (Rosen MJ, Karns R, Vallance JE, Bezold R, Waddell A, Collins MH, Haberman Y, Minar P, Baldassano RN, Hyams JS, Baker SS, Kellermayer R, Noe JD, Griffiths AM, Rosh JR, Crandall WV, Heyman MB, Mack DR, Kappelman MD, Markowitz J, Moulton DE, Leleiko NS, Walters TD, Kugathasan S, Wilson KT, Hogan SP, Denson LA) Gastroenterology 2017 May;152(6):1345-1357.e7 66 Citations |
| 1 | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. (Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB) J Am Acad Dermatol 2017 Mar;76(3):418-431 714 Citations |
| 2 | Effects of anticipated neonatal surgical intervention on maternal milk cytokine production. (Rentea RM, Wagner AJ, Gourlay DM, Christensen M, Liedel JL) J Pediatr Surg 2017 Jan;52(1):45-49 4 Citations |
| 1 | Translating the Science of Psoriasis. (Gordon KB) Semin Cutan Med Surg 2016 Jun;35(4 Suppl 4):S64 3 Citations |
| 1 | A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. (Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K) N Engl J Med 2015 Jul 09;373(2):136-44 293 Citations |
| 1 | Interleukin-23 Increases Intestinal Epithelial Cell Permeability In Vitro. (Heinzerling NP, Donohoe D, Fredrich K, Gourlay DM, Liedel JL) Eur J Pediatr Surg 2016 Jun;26(3):260-6 6 Citations |
| 1 | Oral-resident natural Th17 cells and γδ T cells control opportunistic Candida albicans infections. (Conti HR, Peterson AC, Brane L, Huppler AR, Hernández-Santos N, Whibley N, Garg AV, Simpson-Abelson MR, Gibson GA, Mamo AJ, Osborne LC, Bishu S, Ghilardi N, Siebenlist U, Watkins SC, Artis D, McGeachy MJ, Gaffen SL) J Exp Med 2014 Sep 22;211(10):2075-84 237 Citations |
| 1 | New and emerging therapies in psoriasis. (Leonardi CL, Gordon KB) Semin Cutan Med Surg 2014 Mar;33(2 Suppl 2):S37-41 22 Citations |
| 1 | Rationale and early clinical data on IL-17 blockade in psoriasis. (Nwe SM, Champlain AH, Gordon KB) Expert Rev Clin Immunol 2013 Jul;9(7):677-82 15 Citations |
| 1 | Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. (Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B) J Eur Acad Dermatol Venereol 2013 Oct;27(10):1252-61 64 Citations |
| 1 | A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. (Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM) J Invest Dermatol 2012 Feb;132(2):304-14 158 Citations |
| 1 | Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. (Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A) JAMA 2011 Aug 24;306(8):864-71 279 Citations |
| 1 | Plasmin plays an essential role in amplification of psoriasiform skin inflammation in mice. (Li Q, Ke F, Zhang W, Shen X, Xu Q, Wang H, Yu XZ, Leng Q, Wang H) PLoS One 2011 Feb 02;6(2):e16483 35 Citations |
| 1 | Adenoviral-transduced dendritic cells are susceptible to suppression by T regulatory cells and promote interleukin 17 production. (Wang AY, Crome SQ, Jenkins KM, Medin JA, Bramson JL, Levings MK) Cancer Immunol Immunother 2011 Mar;60(3):381-8 3 Citations |
| 1 | Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. (Gandhi M, Alwawi E, Gordon KB) Semin Cutan Med Surg 2010 Mar;29(1):48-52 58 Citations |
| 2 | Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. (Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR) Blood 2009 Mar 05;113(10):2352-62 72 Citations |
| 1 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). (Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 study investigators) Lancet 2008 May 17;371(9625):1675-84 1427 Citations |
| 1 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). (Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 study investigators) Lancet 2008 May 17;371(9625):1665-74 1615 Citations |
| 1 | Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R) J Am Acad Dermatol 2008 May;58(5):826-50 1266 Citations |
| 1 | Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. (Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, ABT-874 Psoriasis Study Investigators) Arch Dermatol 2008 Feb;144(2):200-7 222 Citations |
